Aterosclerose: Acesso Aberto

Abstrato

The Atherosclerosis and Lipid Lowering- is there a Need for New Agents

Leonardo Roever

Statins has substantially reduced CVD events around the world and is recommended as firstlLne therapy for CVD management. However, a need for other lipid-lowering agents, because some patients do not tolerate statins due to adverse events, or cannot reach LDL-C level desired because of high levels of LDL-C, or patients with very high risk cardiovascular events need more intensive reduction therapy [7-9]. Can we pay the benefits of these new agents when statins are eوٴectLve and inexpensive? Zhang et al. reported a meta-analysis study to evaluate the safety and eٹcac\ of anti-PCSK9 antibodies in randomized, controlled trials (RCTs). 7went\five RCTs encompassing 12,200 patients were included. Нe study showing largely no sLJnLficant dLوٴerence between anti-PCSK9 antibodies and placebo (or ezetimibe), except that alirocumab was associated with reduced rates of death (relative risk (RR): 0.43, 95 % CI: 0.19 to 0.96, P=0.04) and an increased rate of injection-site reactions (RR: 1.48, 95 % CI: 1.05 to 2.09, P=0.02)